Faithward Advisors LLC Buys New Position in United Therapeutics Corporation $UTHR

Faithward Advisors LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, Holdings Channel.com reports. The firm bought 7,269 shares of the biotechnology company’s stock, valued at approximately $3,542,000.

Several other large investors have also bought and sold shares of the company. Darwin Global Management Ltd. bought a new position in United Therapeutics during the third quarter valued at about $317,617,000. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $293,418,000. Dimensional Fund Advisors LP lifted its holdings in shares of United Therapeutics by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 528,210 shares of the biotechnology company’s stock valued at $257,405,000 after purchasing an additional 15,394 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $157,390,000. Finally, Victory Capital Management Inc. lifted its holdings in shares of United Therapeutics by 108.1% during the fourth quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock valued at $111,280,000 after purchasing an additional 118,628 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on UTHR. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Stock Up 0.7%

Shares of NASDAQ UTHR opened at $549.57 on Tuesday. The business has a fifty day simple moving average of $566.45 and a 200-day simple moving average of $522.10. The company has a market cap of $23.33 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.63 earnings per share. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,712,246.04. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $549.29, for a total value of $5,492,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,368,398.04. This represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 634,468 shares of company stock valued at $357,970,302. Corporate insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.